The Omics Brief | Beyond Blood: How Saliva Protein Assays are Driving Decentralized Clinical Trials

First up: saliva proteomics. In this brief, we break down the signals – both in the pharma and biotech industry and within saliva samples themselves – that are propelling decentralized clinical trial (DCT) models forward. Studies show that DCTs improve patient recruitment and retention while cutting trial time and costs, and regulatory bodies are drafting guidance that shows an interest in helping trials to adopt decentralized approaches.

Non-invasive testing is critical in enabling DCT designs, allowing for remote sample collection and increasing patient compliance with patient-friendly sampling. We explore how saliva protein assays provide a unique advantage on this front, providing rich insights into systemic health and drug response from a single swab.